The Latest SPAC News and Rumors: November 18, 2021
by Marlena Haddad on 2021-11-18 at 11:43am

Below is a daily summary of links to theca latest SPAC news and rumors gathered across the web. 

Latest SPAC News: PrimeBlock in talks to merge with 10X SPAC, Lucid’s 440% surge draws tepid interest from analysts, and SEC probes ATI Physical Therapy on earnings guidance


Bitcoin Firm PrimeBlock In Talks to Merge With 10X SPAC

Prime Blockchain Inc., a Bitcoin mining and infrastructure firm, is in talks to merge with special purpose acquisition company 10X Capital Venture Acquisition Corp. II (NASDAQ:VCXA), according to Bloomberg.

The SPAC is seeking to raise at least $150 million through a PIPE to support the transaction, which is set to take Prime Blockchain public and value the combined entity at roughly $1.5 billion.

READ

Lucid’s 440% Jump Draws Tepid Interest From Street Analysts

Lucid Group Inc. (NASDAQ: LCID) has become a darling of retail traders during this year’s 440% climb. Wall Street analysts, though, are a different matter.

The third-largest U.S. electric-vehicle startup, which now commands a bigger market value than Ford Motor Co. (NYSE:F), is covered by only three Wall Street analysts, according to data compiled by Bloomberg. That makes it the least covered stock after Berkshire Hathaway Inc. (NYSE:BRK.A) among U.S. companies with a market capitalization of more than $70 billion.

READ

SEC Probes SPAC-Backed ATI Physical Therapy on Earnings Guidance

ATI Physical Therapy Inc. (NYSE:ATIP), a rehabilitation services firm that merged with a blank-check company earlier this year, said it received an information request from federal securities regulators tied to an earnings forecast.

The Securities and Exchange Commission asked ATI on Nov. 5 for documents and financial information tied to the company’s July 26 earnings projection, which drastically cut earlier guidance, according to a Wednesday regulatory filing.

READ

Senator Elizabeth Warren Calls on SEC to Investigate Trump SPAC Deal

Sen. Elizabeth Warren on Thursday asked the Securities and Exchange Commission to investigate a planned SPAC deal involving former President Donald Trump’s planned social media platform.

Warren, a Massachusetts Democrat, in a letter to SEC Chairman Gary Gensler noted recent news reports that Digital World Acquisition Corp. (NASDAQ:DWAC), which last month announced plans to merge with Trump’s new company, “may have committed securities violations by holding private and undisclosed discussions about the merger as early as May 2021, while omitting this information filing and other public statements.”

READ

Gelesis Receives $30 Million Plenity Order from Ro

Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity. Plenity was initially made available through a beta launch in 2020, and demand quickly outpaced supply while Gelesis worked to construct a larger manufacturing facility. Gelesis’ first commercial-scale manufacturing line at the facility is now complete and validated.

Gelesis and Capstar Special Purpose Acquisition Corp. (NYSE: CPSR) announced in July that they entered into a definitive business combination agreement.

READ


EQRx and Evotec Announce Integrated Drug Discovery and Development Partnership

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE (NASDAQ: EVO), a leading life science company, today announced a collaboration to design, discover and develop new therapeutic options for patients.

The collaboration will help accelerate EQRx’s pipeline expansion efforts by leveraging Evotec’s unique data-driven, fully integrated R&D platform, applied across different drug modalities and therapeutic areas. This approach aims to expedite the invention and development of novel drugs and helps ensure superior translation from research ideas to safe and efficacious medicines.

 In August 2021, EQRx announced a proposed combination with CM Life Sciences III (NASDAQ: CMLTU) to accelerate its growth. The combination is expected to be completed in the fourth quarter of 2021.

READ


Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved